At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 70 enrolled
Drug / intervention
Sirolimusdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma: Long-Term Outcomes and Side Effects
In Brief
A Phase 3 clinical trial evaluating Sirolimus for Liver Carcinoma. Completed, enrolled 70 participants across 1 site.
Detailed Summary
This study investigates whether sirolimus could decrease the rate of hepatoma recurrence after liver transplantation in high risk hepatoma patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Carcinoma
CountriesCanada
Collaborators--
Timeline
Phase 3CompletedFinished
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 1996
Primary CompletionMar 2006
First PostedMay 2006
TodayJul 2026
First PostedMay 22, 2006
Enrollment StartDec 1, 1996
Primary CompletionMar 1, 2006
TodayJul 2, 2026
Enrollment to primary: 9.3 yearsPosted 20.1 years ago
Interventions
Sirolimusdrug
Sirolimus given intravenously or orally to achieve target levels of 12-20ug/l